Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke.
Laura Marie SawyerKlaus K WitteMatthew R ReynoldsSuneet MittalFrank W Grimsey JonesSarah C RosemasPaul D ZieglerRachelle E KaplonShadi YaghiPublished in: Journal of comparative effectiveness research (2020)
Background: We assessed cost-effectiveness of insertable cardiac monitors (ICMs) in a US cryptogenic stroke population. Materials & methods: We modelled lifetime costs and quality-adjusted life years for three monitoring strategies post cryptogenic stroke: ICM starting immediately, ICM starting after Holter monitoring (delayed ICM) and standard of care involving intermittent ECG and Holter monitoring. Patient characteristics and detection efficacy were based on the CRYSTAL-AF trial. AF detection altered the modelled anticoagulation therapy and subsequent stroke and bleed risks. Results & conclusion: Immediate ICM was found to be cost-effective versus standard of care and cost-saving versus delayed ICM. Results were robust to sensitivity analyses. ICMs are a cost-effective diagnostic tool for the prevention of recurrent stroke in a US cryptogenic stroke population.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- left atrial
- left atrial appendage
- catheter ablation
- direct oral anticoagulants
- heart failure
- healthcare
- percutaneous coronary intervention
- randomized controlled trial
- palliative care
- clinical trial
- mesenchymal stem cells
- study protocol
- quality improvement
- heart rate
- coronary artery disease
- bone marrow
- mitral valve
- high intensity
- label free
- sensitive detection